|
Market Closed -
Nasdaq
16:00:00 2026-09-08 EDT
|
5-day change | 1st Jan Change | ||
| 9.065 USD | -8.99% |
|
-8.62% | +16.22% |
| 09-08 | Pharvaris' genetic disorder drug meets main goal in late-stage trial | RE |
| 08-25 | BioCryst Pharmaceuticals Announces Approval Of ORLADEYO For Pediatric HAE Patients In Japan | CI |
Company Valuation: BioCryst Pharmaceuticals, Inc.
Data adjusted to current consolidation scope
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|---|---|---|
| Market Cap 1 | 2,492 | 2,140 | 1,227 | 1,558 | 1,642 | 2,316 | - | - |
| Change | - | -14.12% | -42.68% | 26.97% | 5.43% | 41.05% | - | - |
| Enterprise Value (EV) | 2,124 | 2,140 | 1,654 | 2,065 | 1,642 | 2,316 | 2,316 | 2,316 |
| Change | - | 0.77% | -22.74% | 24.91% | -20.49% | 41.05% | 0% | 0% |
| P/E | -13.4x | -8.63x | -5.08x | -17.5x | 6.45x | -3.95x | 13.6x | 10.7x |
| PBR | -23.9x | -7.32x | -2.71x | -3.27x | - | -7.42x | -199x | 4.91x |
| PEG | - | -0.3x | 0.5x | 0.3x | -0x | 0x | -0x | 0.4x |
| Capitalization / Revenue | 15.9x | 7.9x | 3.7x | 3.46x | 1.88x | 3.3x | 3.14x | 2.77x |
| EV / Revenue | 0x | 0x | 0x | 0x | 0x | 3.3x | 3.14x | 2.77x |
| EV / EBITDA | -0x | -0x | -0x | -0x | 0x | -4.65x | 11.3x | - |
| EV / EBIT | -0x | -0x | -0x | -0x | 0x | -4.56x | 9.37x | 7.18x |
| EV / FCF | -0x | -0x | -0x | -0x | 0x | -37.5x | 8.41x | 5.83x |
| FCF Yield | -5.8% | -7.63% | -7.93% | -3.41% | 21% | -2.67% | 11.9% | 17.2% |
| Dividend per Share 2 | - | - | - | - | - | - | - | - |
| Rate of return | - | - | - | - | - | - | - | - |
| EPS 2 | -1.03 | -1.33 | -1.18 | -0.43 | 1.21 | -2.296 | 0.6647 | 0.8435 |
| Distribution rate | - | - | - | - | - | - | - | - |
| Net sales 1 | 157.2 | 270.8 | 331.4 | 450.7 | 874.8 | 702.2 | 737.3 | 837.3 |
| EBITDA 1 | -176.9 | -147 | -102.1 | -1.297 | 342.4 | -497.8 | 204.5 | - |
| EBIT 1 | -177.7 | -148.4 | -103.7 | -2.543 | 341 | -508.2 | 247.2 | 322.4 |
| Net income 1 | -184.1 | -247.1 | -226.5 | -88.88 | 263.9 | -578.8 | 184.4 | 253.9 |
| Net Debt | -368.3 | - | 426.7 | 507.7 | - | - | - | - |
| Reference price 2 | 13.850 | 11.480 | 5.990 | 7.520 | 7.800 | 9.065 | 9.065 | 9.065 |
| Nbr of stocks (in thousands) | 179,936 | 186,424 | 204,809 | 207,133 | 210,543 | 255,535 | - | - |
| Announcement Date | 2/23/22 | 2/21/23 | 2/26/24 | 2/24/25 | 2/26/26 | - | - | - |
1USD in Million2USD
Estimates
P/E, Detailed evolution
| P/E (Y) | EV / Sales (Y) | EV / EBITDA (Y) | Dividend Yield (Y) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -3.95x | - | - | -.--% | 2.32B | |
| 20.31x | 7.19x | 14.43x | 1.46% | 69.19B | |
| 35.78x | 9.33x | 28.47x | 0.04% | 62.97B | |
| -76.45x | 14.75x | -71.13x | -.--% | 27.27B | |
| -14.89x | 5.5x | -6.92x | -.--% | 24.78B | |
| 29.76x | 6.36x | 16.51x | -.--% | 25.8B | |
| 27.41x | 5.13x | 17.28x | -.--% | 20.11B | |
| 52.99x | 19.62x | 39.8x | 0.28% | 18.47B | |
| 1285.53x | 37.11x | 809.82x | -.--% | 14.88B | |
| 17.81x | 5.31x | 12.39x | -.--% | 14.29B | |
| Average | 137.43x | 12.26x | 95.63x | 0.18% | 28.01B | |
| Weighted average by Cap. | 81.65x | 10.37x | 51.89x | 0.39% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
Year-on-year evolution of the Yield
- Stock Market
- Stocks
- BCRX Stock
- Valuation BioCryst Pharmaceuticals, Inc.
Select your edition
All financial news and data tailored to specific country editions
